3/27
08:17 pm
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Medium
Report
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
3/25
04:45 pm
nuvb
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
Medium
Report
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
3/25
08:34 am
nuvb
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025 [Yahoo! Finance]
Low
Report
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025 [Yahoo! Finance]
3/25
08:00 am
nuvb
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
Neutral
Report
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
3/14
06:13 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) was upgraded by analysts at Jones Trading to a "strong-buy" rating.
Medium
Report
Nuvation Bio Inc. (NYSE: NUVB) was upgraded by analysts at Jones Trading to a "strong-buy" rating.
3/12
08:57 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) is now covered by analysts at Jones Trading. They set a "buy" rating and a $10.00 price target on the stock.
Medium
Report
Nuvation Bio Inc. (NYSE: NUVB) is now covered by analysts at Jones Trading. They set a "buy" rating and a $10.00 price target on the stock.
3/10
08:03 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its price target lowered by analysts at HC Wainwright from $11.00 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
Nuvation Bio Inc. (NYSE: NUVB) had its price target lowered by analysts at HC Wainwright from $11.00 to $10.00. They now have a "buy" rating on the stock.
3/6
05:17 pm
nuvb
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
3/6
04:30 pm
nuvb
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Medium
Report
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
3/4
06:24 am
nuvb
Nuvation Bio secures $250m for taletrectinib commercialisation [Yahoo! Finance]
High
Report
Nuvation Bio secures $250m for taletrectinib commercialisation [Yahoo! Finance]
3/3
06:30 pm
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Low
Report
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
3/3
08:46 am
nuvb
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners [Yahoo! Finance]
High
Report
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners [Yahoo! Finance]
3/3
08:35 am
nuvb
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
Medium
Report
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
2/24
08:46 am
nuvb
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference [Yahoo! Finance]
Medium
Report
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference [Yahoo! Finance]
2/24
08:00 am
nuvb
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference
High
Report
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference
2/18
01:49 pm
nuvb
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
2/3
08:36 am
nuvb
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer [Yahoo! Finance]
Low
Report
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer [Yahoo! Finance]
2/3
08:00 am
nuvb
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer
Low
Report
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer
1/23
08:02 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its price target raised by analysts at HC Wainwright from $10.00 to $11.00. They now have a "buy" rating on the stock.
Medium
Report
Nuvation Bio Inc. (NYSE: NUVB) had its price target raised by analysts at HC Wainwright from $10.00 to $11.00. They now have a "buy" rating on the stock.
1/7
10:25 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock, up previously from $6.00.
Medium
Report
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock, up previously from $6.00.
1/6
06:32 pm
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
High
Report
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
1/6
04:30 pm
nuvb
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
High
Report
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/6
04:05 pm
nuvb
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
High
Report
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
1/6
08:19 am
nuvb
Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer [Yahoo! Finance]
Low
Report
Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer [Yahoo! Finance]
1/6
08:14 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Nuvation Bio Inc. (NYSE: NUVB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.